Announcements
- Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial
- Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events
- Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer
- Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events
- Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024
- Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
- Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
- Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events
- Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.10 |
---|---|
High | 3.12 |
Low | 3.10 |
Bid | 2.98 |
Offer | 3.26 |
Previous close | 3.12 |
Average volume | 344.44 |
---|---|
Shares outstanding | 8.31m |
Free float | 6.75m |
P/E (TTM) | -- |
Market cap | 28.49m USD |
EPS (TTM) | -2.46 USD |
Data delayed at least 15 minutes, as of Jul 04 2024 12:08 BST.
More ▼